Susan Moran
Directeur/Membre du Conseil chez BIOATLA, INC.
Fortune : 39 466 $ au 30/06/2024
Profil
Susan Moran is an Independent Director at BioAtla, Inc. since 2020 and at Tyra Biosciences, Inc. since 2024.
She previously worked as a Medical Director at Millennium Pharmaceuticals, Inc. from 2011 to 2014, as a Senior Medical Director at Genzyme Therapeutics Ltd.
from 2007 to 2011, as the Vice President & Head-Clinical Development at Puma Biotechnology, Inc. from 2016 to 2018, as the Chief Medical Officer at QED Therapeutics, Inc. from 2018 to 2021, and as the Chief Medical Officer at Rayzebio, Inc. from 2021 to 2024.
Dr. Moran completed her undergraduate degree at Duke University and her graduate degree at the University of Pennsylvania Medical Center.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BIOATLA, INC.
0,06% | 13/06/2024 | 28 807 ( 0,06% ) | 39 466 $ | 30/06/2024 |
TYRA BIOSCIENCE, INC
-.--% | 07/05/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Susan Moran
| Sociétés | Poste | Début |
|---|---|---|
| BIOATLA, INC. | Directeur/Membre du Conseil | 01/12/2020 |
| TYRA BIOSCIENCES, INC. | Directeur/Membre du Conseil | 07/05/2024 |
Anciens postes connus de Susan Moran
| Sociétés | Poste | Fin |
|---|---|---|
| RAYZEBIO, INC. | Directeur Technique/Scientifique/R&D | 01/05/2024 |
QED Therapeutics, Inc.
 QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Directeur Technique/Scientifique/R&D | 01/06/2021 |
| PUMA BIOTECHNOLOGY, INC. | Directeur Technique/Scientifique/R&D | 01/02/2018 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Directeur Technique/Scientifique/R&D | 01/01/2014 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Directeur Technique/Scientifique/R&D | 01/01/2011 |
Formation de Susan Moran
| University of Virginia | Undergraduate Degree |
| University of Pennsylvania Medical Center | Graduate Degree |
| Duke University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| BIOATLA, INC. | Health Technology |
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| RAYZEBIO, INC. | Health Technology |
| TYRA BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
